Advertisement

Rheumatology International

, Volume 39, Issue 10, pp 1689–1695 | Cite as

Mental disorders in systemic lupus erythematosus: a cohort study

  • Heidi Fernandez
  • Andrea Cevallos
  • Ruth Jimbo SotomayorEmail author
  • Fernando Naranjo-Saltos
  • Diego Mera Orces
  • Efrain Basantes
Cohort Studies
  • 62 Downloads

Abstract

Currently, the evaluation of mental disorders in patients with Systemic lupus erythematosus (SLE) is essential in the management of the illness because of their impact in morbimortality. The main purpose of this study was to determine the prevalence of mental disorders in a group of patients with SLE in a tertiary referral hospital in Quito-Ecuador. The main diffuse central nervous system psychiatric syndromes in SLE (psychosis, anxiety and mood disorders) and cognitive dysfunction were evaluated with the MINI International Neuropsychiatric Interview and the Montreal scale, respectively. This was a descriptive, cross-sectional study which included patients 15 years and older diagnosed with SLE in a tertiary referral hospital in Quito, Ecuador. 85 patients diagnosed with SLE attending the internal medicine outpatient clinic during October 2017–May 2018 were included. A bivariate analysis of possible associations between these mental disorders with corticosteroid use, antiphospholipid syndrome (APS), and quality of life was also studied. Eighty-five patients, with an average age of 34.12 ± 11.5 years were included, of which 94% were females. 71% of participants (60 patients) had at least one mental disorder evaluated in this study. The most frequent was cognitive impairment (n = 43, 51%) followed by anxiety disorders (n = 35, 41%), mood disorders (n = 34, 40%) and psychosis (n = 1; 1%). 38% presented mild cognitive impairment and 13% had moderate cognitive impairment. Memory and visuospatial/executive function were the most affected domains in the cognitive assessment. 38% of participants were previously diagnosed with antiphospholipid syndrome, of which 78% had a mental disorder (OR = 1.83, p = 0.2). Most patients (n = 84; 99%) were treated with corticosteroids, of these, 59 patients presented a mental disorder (OR = 0.9, p = 0.8). Associations with APS or corticosteroid use were not statistically significant. However, the multivariate regression suggests an association between presence of mental disease and quality of life. There were statistically significant alterations in anxiety/depression and pain. There is a high prevalence of neuropsychiatric syndromes in this cohort of patients. Almost ¾ of our cohort had at least one mental disorder, the most common was cognitive impairment.

Keywords

Systemic lupus erythematosus Mental disorders Psychiatric syndromes Cognitive disorders Quality of life 

Notes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

HF declares no conflict of interest; AC declares no conflict of interest; RJS declares no conflict of interest; FN-S declares no conflict of interest; DM declares no conflict of interest; EB declares no conflict of interest.

Research involving human participants

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Eugenio Espejo Hospital-Ministry of Public Health) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by hospital authorities and the Human Research Ethics Committee.

Informed consent

Written informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    ACR Ad Hoc Committee on neuropsychiatric lupus nomenclature (1999) The American Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42(4):599–608.  https://doi.org/10.1002/1529-0131(199904)42:4%3c599:AID-ANR2%3e3.0.CO;2-F CrossRefGoogle Scholar
  2. 2.
    León T, Henríquez C, Calderón J, Massardo L (2012) Actualización en lupus neuro-psiquiátrico con énfasis en déficit cognitivo. Revista Médica de Chile 140(10):1333–1341.  https://doi.org/10.4067/S0034-98872012001000015 CrossRefGoogle Scholar
  3. 3.
    Aguilera-Pickens G, Abud-Mendoza C (2013) Manifestaciones neuropsiquiátricas en lupus eritematoso generalizado: bases fisiopatogénicas y terapéuticas. Reumatología Clínica 9(6):331–333.  https://doi.org/10.1016/j.reuma.2013.02.007 CrossRefGoogle Scholar
  4. 4.
    Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, Peschken C (2012) Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 42(2):179–185.  https://doi.org/10.1016/j.semarthrit.2012.03.011 CrossRefGoogle Scholar
  5. 5.
    Dorman G, Micelli M, Cosentino V, Ottone L, Nuñez MR, Mangone C, Genovese O (2017) Disfunción cognitiva en lupus eritematoso sistémico y su asociación con actividad y daño. Medicina (Buenos Aires) 2017(77):257–260Google Scholar
  6. 6.
    Kulczycka L, Sysa-Jȩdrzejowska A, Robak E (2010) Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations. Clin Rheumatol 29(9):991–997.  https://doi.org/10.1007/s10067-010-1509-0 CrossRefGoogle Scholar
  7. 7.
    Petri et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686.  https://doi.org/10.1002/art.34473 CrossRefGoogle Scholar
  8. 8.
    Remiao M et al (2017) Update on antiphospholipid antibody syndrome. Rev Assoc Med Bras 63(11):994–999.  https://doi.org/10.1590/1806-9282.63.11.994 CrossRefGoogle Scholar
  9. 9.
    Paez-venegas N, Jordan-estrada B, Chavarria-avila E (2018) The montreal cognitive assessment test a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. JCR J Clin Rheumatol 1:4.  https://doi.org/10.1097/RHU.0000000000000802 Google Scholar
  10. 10.
    Schwartz N, Stock AD, Putterman C (2019) Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol.  https://doi.org/10.1038/s41584-018-0156-8 Google Scholar
  11. 11.
    Unterman A, Nolte JES, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G (2011) Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 41(1):1.  https://doi.org/10.1016/j.semarthrit.2010.08.001 CrossRefGoogle Scholar
  12. 12.
    Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A (2001) The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57:496–500.  https://doi.org/10.1212/wnl.57.3.496 CrossRefGoogle Scholar
  13. 13.
    Bertsias GK, Boumpas DT (2010) Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 6:358–367.  https://doi.org/10.1038/nrrheum.2010.62 CrossRefGoogle Scholar
  14. 14.
    Borowoy AM et al (2012) Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 Faces of Lupus cohort. Semin Arthritis Rheum 42:179–185.  https://doi.org/10.1016/j.semarthrit.2012.03.011 CrossRefGoogle Scholar
  15. 15.
    Wekking EM (1993) Psychiatric Symptoms in Systemic Lupus Erythematosus: an Update. Psychosom Med 55(2):219–228CrossRefGoogle Scholar
  16. 16.
    Jarpa E, Babul M, Calderon J, Gonzalez M, Martinez ME, Bravo-Zehnder M, Massardo L (2011) Common mental disorders and psychological distress in systemic lupus erythematosus are not associated with disease activity. Lupus 20(1):58–66.  https://doi.org/10.1177/0961203310381773 CrossRefGoogle Scholar
  17. 17.
    Hanly et al (2011) Prospective analysis of neuropsychiatric events in an international disease inception cohort of SLE patients. Ann Rheum Dis 69(3):529–535.  https://doi.org/10.1136/ard.2008.106351.Prospective CrossRefGoogle Scholar
  18. 18.
    Kivity S, Agmon-Levin N, Zandman-Goddard G, Chapman J, Shoenfeld Y (2015) Neuropsychiatric lupus: a mosaic of clinical presentations. BMC Med 13(1):1–11.  https://doi.org/10.1186/s12916-015-0269-8 CrossRefGoogle Scholar
  19. 19.
    Govoni M, Bortoluzzi A, Padovan M, Silvagni E, Borrelli M, Donelli F (2018) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 74(2016):41–72.  https://doi.org/10.1016/j.jaut.2016.06.01 Google Scholar
  20. 20.
    Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, McGlasson D (2002) Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58(8):1214–1220.  https://doi.org/10.1212/WNL.58.8.1214 CrossRefGoogle Scholar
  21. 21.
    Zhang L, Fu T, Yin R, Zhang Q, Shen B (2017) Prevalence of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. BMC Psychiatry.  https://doi.org/10.1186/s12888-017-1234-1 Google Scholar
  22. 22.
    Jorge Asano NM, de Sales Wanderley, Coriolano M, Das G, Jorge Asano B, Gomes Lins O (2013) Psychiatric comorbidities in patients with systemic lupus erythematosus: a systematic review of the last 10 years. Revista Brasileira de Reumatologia (English Edition) 53(5):431–437.  https://doi.org/10.1016/S2255-5021(13)70114-7 CrossRefGoogle Scholar
  23. 23.
    Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S (2013) Depression and systemic lupus erythematosus: a systematic review. Lupus 22(5):409–416.  https://doi.org/10.1177/0961203313477227 CrossRefGoogle Scholar
  24. 24.
    Stojanovich L, Zandman-Goddard G, Pavlovich S, Sikanich N (2007) Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev 6(6):421–426.  https://doi.org/10.1016/j.autrev.2007.02.007 CrossRefGoogle Scholar
  25. 25.
    Pego-reigosa JM, Isenberg DA (2008) Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology 47(10):1498–1502.  https://doi.org/10.1093/rheumatology/ken260 CrossRefGoogle Scholar
  26. 26.
    Shen B, Tan W, Feng G, He Y, Liu J, Chen W, Gu Z (2013) The correlations of disease activity, socioeconomic status, quality of life, and depression/anxiety in Chinese patients with systemic lupus erythematosus. Clin Dev Immunol 2013:270878.  https://doi.org/10.1155/2013/270878 CrossRefGoogle Scholar
  27. 27.
    Etchegaray-Morales I, Méndez-Martínez S, Jiménez-Hernández C, Mendoza-Pinto C, Alonso-García NE, Montiel-Jarquín A, García-Carrasco M (2017) Factors associated with health-related quality of life in Mexican lupus patients using the LupusQoL. PLoS One 12(1):1–10.  https://doi.org/10.1371/journal.pone.0170209 CrossRefGoogle Scholar
  28. 28.
    Muhammed H, Goyal M, Lal V, Singh S, Dhir V (2018) Neuropsychiatric manifestations are not uncommon in Indian lupus patients and negatively affect quality of life. Lupus 27(4):688–693.  https://doi.org/10.1177/0961203317747720 CrossRefGoogle Scholar
  29. 29.
    Bortoluzzi A, Scirè CA, Govoni M (2018) Attribution of neuropsychiatric manifestations to systemic lupus erythematosus. Front Med 5:1–5.  https://doi.org/10.3389/fmed.2018.00068 CrossRefGoogle Scholar
  30. 30.
    Volpe BT (2016) Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosus. Systemic lupus erythematosus: basic, applied and clinical aspects. Elsevier, Manhasset.  https://doi.org/10.1016/B978-0-12-801917-7.00036-X Google Scholar
  31. 31.
    Clark K (2017) A critical analysis of the tools to evaluate neuropsychiatric lupus. Lupus 26(5):504–509.  https://doi.org/10.1177/0961203317690242 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineEugenio Espejo HospitalQuitoEcuador
  2. 2.Postgrado de Medicina InternaPontificia Universidad Católica del EcuadorQuitoEcuador

Personalised recommendations